← Leaderboards

Theresa L. Whiteside

University Of Pittsburgh At Pittsburgh

Google Scholar ↗PubMed ↗ORCID ↗

$29,550,469

Attributed

$33,084,932

Total exposure

28

Grants

21

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$45,447,868 · 30

By mechanism

P01$18,758,152 · 11

P50$9,489,735 · 6

R01$7,478,319 · 5

P30$5,351,984 · 5

U01$3,478,264 · 1

R21$891,414 · 2

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Rajiv Dhir$8,351,145
John Munn Kirkwood$15,450,309
Michael John Becich$31,335,131
David Lewis$20,577,870
Cristian L Achim$16,124,362

Others in their field

Top investigators on “Malignant Neoplasms”

David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
Richard K. Wilson · Washington University$274,272,747
Larry Arthur$223,443,122
Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879

Research focus

Malignant NeoplasmsLaboratoriesBaseProgramsTumorCellsResponseImmune ResponseImmunotherapyResearch PersonnelClinical TrialsBody FluidsLinkSamplingMonitorHead And Neck CancerCytokineEvaluationImmunologicsT-LymphocytePreparationGenerationsPeripheral BloodImmune Function

Grant awards (127)

Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$700,037

R01 · FY2025 · DE · contact PI

The Adenosinergic Pathway in Tumor-derived Exosomes$502,792

R01 · FY2025 · CA · contact PI

Depleting exosomes to improve responses to immune therapy in HNSCC$699,220

U01 · FY2024 · DE · contact PI

Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$686,036

R01 · FY2024 · DE · contact PI

The Adenosinergic Pathway in Tumor-derived Exosomes$477,653

R01 · FY2024 · CA · contact PI

Core 1: Biospecimen and Translational Pathology Core$286,076

P50 · FY2024 · CA · contact PI

Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$130,976

R01 · FY2024 · DE · contact PI

Depleting exosomes to improve responses to immune therapy in HNSCC$718,185

U01 · FY2023 · DE · contact PI

Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer$640,719

R01 · FY2023 · DE · contact PI

The Adenosinergic Pathway in Tumor-derived Exosomes$492,737

R01 · FY2023 · CA · contact PI

Core 1: Biospecimen and Translational Pathology Core$277,134

P50 · FY2023 · CA · contact PI

Depleting exosomes to improve responses to immune therapy in HNSCC$713,327

U01 · FY2022 · DE · contact PI

The Adenosinergic Pathway in Tumor-derived Exosomes$491,088

R01 · FY2022 · CA · contact PI

Core 1: Biospecimen and Translational Pathology Core$278,515

P50 · FY2022 · CA · contact PI

Depleting exosomes to improve responses to immune therapy in HNSCC$720,532

U01 · FY2021 · DE · contact PI

The Adenosinergic Pathway in Tumor-derived Exosomes$510,187

R01 · FY2021 · CA · contact PI

Immunologic Monitoring and Cellular Products Laboratory$1,197,257

P30 · FY2020 · CA · contact PI

Depleting exosomes to improve responses to immune therapy in HNSCC$627,000

U01 · FY2020 · DE · contact PI

Immunologic Monitoring and Cellular Products Laboratory$509,273

P30 · FY2020 · CA · contact PI

Career Development Program$1,150,358

P50 · FY2019 · CA · contact PI

Immunologic Monitoring and Cellular Products Laboratory$532,212

P30 · FY2019 · CA · contact PI

Career Development Program$1,039,841

P50 · FY2018 · CA · contact PI

Career Development Program$1,263,354

P50 · FY2017 · CA · contact PI

Restoring anti-tumor immunity in the microenvironment of head and neck cancer$319,550

R01 · FY2017 · CA · contact PI

(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy$202,439

R21 · FY2017 · CA · contact PI

Restoring anti-tumor immunity in the microenvironment of head and neck cancer$6,288

R01 · FY2017 · CA · contact PI

Career Development Program$1,148,614

P50 · FY2016 · CA · contact PI

Restoring anti-tumor immunity in the microenvironment of head and neck cancer$319,550

R01 · FY2016 · CA · contact PI

(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy$167,475

R21 · FY2016 · CA · contact PI

Restoring anti-tumor immunity in the microenvironment of head and neck cancer$62,293

R01 · FY2016 · CA · contact PI

Restoring anti-tumor immunity in the microenvironment of head and neck cancer$319,550

R01 · FY2015 · CA · contact PI

Career Development Program$73,142

P50 · FY2015 · CA · contact PI

Restoring anti-tumor immunity in the microenvironment of head and neck cancer$309,460

R01 · FY2014 · CA · contact PI

Career Development Program$86,987

P50 · FY2014 · CA · contact PI

Clinical Core$436,178

P01 · FY2013 · CA · contact PI

Restoring anti-tumor immunity in the microenvironment of head and neck cancer$316,438

R01 · FY2013 · CA · contact PI

Career Development Program$186,748

P50 · FY2013 · CA · contact PI

Immunological Monitoring & Cellular Products$519,862

P50 · FY2012 · CA · contact PI

Clinical Core$476,136

P01 · FY2012 · CA · contact PI

Immunological monitoring and cellular products laboratory$120,473

P01 · FY2012 · NS · contact PI

Career Development Program$93,029

P50 · FY2012 · CA · contact PI

Clinical Core$49,495

P01 · FY2012 · CA · contact PI

Immunological Monitoring & Cellular Products$460,523

P50 · FY2011 · CA · contact PI

Immunological monitoring and cellular products laboratory$122,342

P01 · FY2011 · NS · contact PI

Career Development Program$94,528

P50 · FY2011 · CA · contact PI

Clinical Core$23,627

P01 · FY2011 · CA · contact PI

Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications$1,050,724

P01 · FY2010 · CA · contact PI

Immunological Monitoring & Cellular Products$486,889

P50 · FY2010 · CA · contact PI

Apoptosis, Signaling Defects and T Lymphocyte Homeostasis in Patients with Cancer$250,470

P01 · FY2010 · CA · contact PI

IMCPL / Flow Cytometry$155,913

P01 · FY2010 · CA · contact PI

Immunological monitoring and cellular products laboratory$122,920

P01 · FY2010 · NS · contact PI

Career Development Program$105,254

P50 · FY2010 · CA · contact PI

Clinical Core$24,952

P01 · FY2010 · CA · contact PI

Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications$1,196,407

P01 · FY2009 · CA · contact PI

Immunological Monitoring & Cellular Products$488,223

P50 · FY2009 · CA · contact PI

IMCPL / Flow Cytometry$319,070

P01 · FY2009 · CA · contact PI

Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications$303,000

P01 · FY2009 · CA · contact PI

Apoptosis, Signaling Defects and T Lymphocyte Homeostasis in Patients with Cancer$245,871

P01 · FY2009 · CA · contact PI

Immunological monitoring and cellular products laboratory$94,361

P01 · FY2009 · NS · contact PI

Clinical Core$24,733

P01 · FY2009 · CA · contact PI

Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications$1,188,642

P01 · FY2008 · CA · contact PI

CORE--CELLULAR PRODUCTS LABORATORY$326,686

P30 · FY2008 · CA · contact PI

IMCPL / Flow Cytometry$317,124

P01 · FY2008 · CA · contact PI

CORE--IMMUNOLOGICAL MONITORING LABORATORY$316,445

P30 · FY2008 · CA · contact PI

Immunological Monitoring & Cellular Products$308,898

P50 · FY2008 · CA · contact PI

Apoptosis, Signaling Defects and T Lymphocyte Homeostasis in Patients with Cancer$256,647

P01 · FY2008 · CA · contact PI

IMMUNOLOGIC MONITORING AND CELL PRODUCTS LABORATORY$151,402

P01 · FY2008 · CA · contact PI

Immunological monitoring and cellular products laboratory$123,343

P01 · FY2008 · NS · contact PI

Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications$1,081,004

P01 · FY2007 · CA · contact PI

CORE--CELLULAR PRODUCTS LABORATORY$352,080

P30 · FY2007 · CA · contact PI

CORE--IMMUNOLOGICAL MONITORING LABORATORY$342,444

P30 · FY2007 · CA · contact PI

Apoptosis, Signaling Defects and T Lymphocyte Homeostasis in Patients with Cancer$255,473

P01 · FY2007 · CA · contact PI

IMCPL / Flow Cytometry$213,040

P01 · FY2007 · CA · contact PI

IMMUNOLOGIC MONITORING AND CELL PRODUCTS LABORATORY$151,952

P01 · FY2007 · CA · contact PI

Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications$1,071,960

P01 · FY2006 · CA · contact PI

Vaccine Development for Oral Carcinoma$1,005,116

P01 · FY2006 · DE · contact PI

Apoptosis, Signaling Defects and T Lymphocyte Homeostasis in Patients with Cancer$167,756

P01 · FY2006 · CA · contact PI

T-Cell Defined Oral Carcinoma Antigens$157,030

P01 · FY2006 · DE · contact PI

CORE--CELLULAR PRODUCTS LABORATORY$134,368

P30 · FY2006 · CA · contact PI

CORE--IMMUNOLOGICAL MONITORING LABORATORY$131,242

P30 · FY2006 · CA · contact PI

IMCPL / Flow Cytometry$116,922

P01 · FY2006 · CA · contact PI

IMMUNOLOGIC MONITORING AND CELL PRODUCTS LABORATORY$88,160

P01 · FY2006 · CA · contact PI

Administration$68,342

P01 · FY2006 · CA · contact PI

Vaccine Development for Oral Carcinoma$999,323

P01 · FY2005 · DE

DNA-Based Vaccines for Oral Carcnoma$185,806

R01 · FY2005 · DE

T-Cell Defined Oral Carcinoma Antigens$152,456

P01 · FY2005 · DE

CORE--CELLULAR PRODUCTS LABORATORY$130,453

P30 · FY2005 · CA

CORE--IMMUNOLOGICAL MONITORING LABORATORY$127,484

P30 · FY2005 · CA

IMMUNOLOGIC MONITORING AND CELL PRODUCTS LABORATORY$92,554

P01 · FY2005 · CA

Vaccine Development for Oral Carcinoma$970,214

P01 · FY2004 · DE

DNA-Based Vaccines for Oral Carcnoma$245,406

R01 · FY2004 · DE

T-Cell Defined Oral Carcinoma Antigens$148,015

P01 · FY2004 · DE

CORE--CELLULAR PRODUCTS LABORATORY$126,654

P30 · FY2004 · CA

CORE--IMMUNOLOGICAL MONITORING LABORATORY$123,770

P30 · FY2004 · CA

IMMUNOLOGIC MONITORING AND CELL PRODUCTS LABORATORY$89,860

P01 · FY2004 · CA

Vaccine Development for Oral Carcinoma$944,598

P01 · FY2003 · DE

Novel Approaches to the Assessment of Oral Mucosal Immu*$260,021

R21 · FY2003 · DE

T-Cell Defined Oral Carcinoma Antigens$143,704

P01 · FY2003 · DE

Vaccine Development for Oral Carcinoma$926,163

P01 · FY2002 · DE

CORE--BIOLOGICAL ASSESSMENT$312,755

P50 · FY2002 · HL

Novel Approaches to the Assessment of Oral Mucosal Immu*$261,479

R21 · FY2002 · DE

Core--Cellular products$250,404

P30 · FY2002 · CA

Core--Immunologic monitoring$250,404

P30 · FY2002 · CA

DNA-Based Vaccines for Oral Carcnoma$248,081

R01 · FY2002 · DE

CORE--IMMUNOLOGICAL MONITORING AND CELLULAR PRODUCT LAB$210,131

P01 · FY2002 · NS

T-Cell Defined Oral Carcinoma Antigens$139,518

P01 · FY2002 · DE

CORE--IMMUNOLOGIC MONITORING AND DIAGNOSTIC LABORATORY$0

P01 · FY2002 · CA

DEVELOPMENT OF VACCINES FOR ORAL CARCINOMA$824,210

P01 · FY2001 · DE

CORE--BIOLOGICAL ASSESSMENT$312,755

P50 · FY2001 · HL

CORE--BIOLOGICAL ASSESSMENT$312,755

P50 · FY2001 · HL

DNA-Based Vaccines for Oral Carcinoma$295,099

R01 · FY2001 · DE

Core--Cellular products$250,404

P30 · FY2001 · CA

Core--Immunologic monitoring$250,404

P30 · FY2001 · CA

CORE--IMMUNOLOGIC MONITORING AND DIAGNOSTIC LABORATORY$168,360

P01 · FY2001 · CA

ORAL CARCINOMA PEPTIDES RECOGNIZED BY CD8+ AND CD4+ T LYMPHOCYTES$91,531

P01 · FY2001 · DE

Core--Immunologic monitoring$0

P30 · FY2001 · CA

Core--Cellular products$0

P30 · FY2001 · CA

CORE--IMMUNOLOGIC MONITORING AND DIAGNOSTIC LABORATORY$0

P01 · FY2001 · CA

DEVELOPMENT OF VACCINES FOR ORAL CARCINOMA$801,575

P01 · FY2000 · DE

GROWTH INHIBITION BY IL2 OF IL2R+ ORAL CARCINOMAS$218,573

R01 · FY2000 · CA

CORE--BIOLOGICAL ASSESSMENT$203,495

P50 · FY2000 · HL

CORE--IMMUNOLOGIC MONITORING AND DIAGNOSTIC LABORATORY$197,104

P01 · FY2000 · CA

CORE--IMMUNOLOGIC MONITORING AND DIAGNOSTIC LABORATORY$168,360

P01 · FY2000 · CA

CORE--IMMUNOLOGIC MONITORING AND DIAGNOSTIC LABORATORY$168,360

P01 · FY2000 · CA

ORAL CARCINOMA PEPTIDES RECOGNIZED BY CD8+ AND CD4+ T LYMPHOCYTES$91,531

P01 · FY2000 · DE

Core--Immunologic monitoring$0

P30 · FY2000 · CA

Core--Cellular products$0

P30 · FY2000 · CA